Treatment of lung cancer using hedgehog pathway inhibitors
AssigneeHedgepath Pharmaceuticals, Inc.
InventorsNicholas J. Virca, Francis E. O'Donnell, Jr.
Life of this patent
Estimating the term…
Abstract
The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
Claims24
A method for treating lung cancer in a subject, comprising orally administering a composition comprising a solid dispersion of a Hedgehog pathway (HhP) inhibitor and a polycarboxylic acid polymer, to the subject, wherein the HhP inhibitor comprises itraconazole, or a pharmaceutically acceptable salt, prodrug, stereoisomer, or active metabolite thereof;
- and administering an antifolate to the subject, and wherein:
- (a) the composition is orally administered in an effective amount to achieve a plasma trough level of at least about 1,000 ng/mL of the HhP inhibitor, or (b) the composition is orally administered at a dose in the range of 100 mg to 600 mg HhP inhibitor per day.
Dependencies are inferred from the claim text.